Cabazitaxel suppresses colorectal cancer cell growth via enhancing the p53 antitumor pathway

Zhang, Wen; Sun, Rong; Zhang, Yongjun; Hu, Rong; Li, Qian; Wu, Weili; Cao, Xinyu; Zhou, Jiajian; Pei, Jianfeng; Yuan, Ping

doi:10.1002/2211-5463.13290

Cited by 5 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From the perspective of patho- are enriched in PD-L1 negative populations in our study. These findings are all related to oncogenic construction [37][38][39][40]. In previous research on the RTK/RAS pathways in CRC, KRAS mutations have been associated with down-regulation of immune pathways and a reduced number of tumor infiltrating lymphocytes (TILs) [41], which are considered markers for worse sur-vival at all disease stages [42].…”

Section: Discussionmentioning

confidence: 96%

Clinical implications of PD-L1 expression and pathway-related molecular subtypes in advanced Asian colorectal cancer patients

Qiu

2024

Am J Cancer Res

View full text Add to dashboard Cite

The expression level of PD-L1 does not accurately predict the prognosis of advanced colorectal cancer (CRC) patients, but it still reflects the tumor microenvironment to some extent. By stratifying PD-L1 status, gene subtypes in PD-L1 positivity-related pathological pathways were analyzed for their relationship to MSI or TMB to provide more individualized treatment options for CRCs. A total of 752 advanced CRCs were included, and their genomic variance was measured by a targeted next generation sequencing panel in this study. MSI and TMB were both measured by NGS, while PD-L1 expression level was measured using the PD-L1 colon 22C3 pharmDx kit. We found RTK/RAS pathway was positively related to high PD-L1 expression, with BRAF V600E and most KRAS mutations (G12 and G13) subtypes showing a significant correlation. Conversely, the Wnt and p53 pathways were negatively related to high PD-L1 expression, with APC C-terminal alterations and other non-inactivation mutations in TP53 making a primary contribution with significant statistical significance. Major subtypes showing a significantly higher proportion of TMB-H or MSI-H were irrespective of PD-L1 status. These findings demonstrate pathological pathways associated with high PD-L1 expression, suggesting that pathway-induced oncogenic constructive PD-L1 upregulation may be the reason for the corresponding patients' primary resistance to immune checkpoint inhibitors (ICIs), rather than a lack of pre-existing immune responses.

show abstract

Section: Discussionmentioning

confidence: 96%

Clinical implications of PD-L1 expression and pathway-related molecular subtypes in advanced Asian colorectal cancer patients

Qiu

2024

Am J Cancer Res

View full text Add to dashboard Cite

show abstract

“…Cabazitaxel is a more recently added, semi-synthetic paclitaxel analog that was approved by the FDA for the treatment of hormone-refractory metastatic prostate cancer[ 35 ]. Only one report has shown the suppression of CRC cell growth by activating p53 (using HCT116, LOVO, HCT8, and DLD1 cell lines as well as a xenograft model using HCT116)[ 36 ]. Thus, there is a potential to investigate the effectiveness of cabazitaxel in clinical settings, however, so far there are no cabazitaxel clinical trials for CRC.…”

Section: Why Taxanes May Not Work Well In Crcmentioning

confidence: 99%

Recent clinical trials and optical control as a potential strategy to develop microtubule-targeting drugs in colorectal cancer management

Kita,

Burdowski

2024

World J Gastroenterol

View full text Add to dashboard Cite

Colorectal cancer (CRC) has remained the second and the third leading cause of cancer-related death worldwide and in the United States, respectively. Although significant improvement in overall survival has been achieved, death in adult populations under the age of 55 appears to have increased in the past decades. Although new classes of therapeutic strategies such as immunotherapy have emerged, their application is very limited in CRC so far. Microtubule (MT) inhibitors such as taxanes, are not generally successful in CRC. There may be some way to make MT inhibitors work effectively in CRC. One potential advantage that we can take to treat CRC may be the combination of optical techniques coupled to an endoscope or other fiber optics-based devices. A combination of optical devices and photo-activatable drugs may allow us to locally target advanced CRC cells with highly potent MT-targeting drugs. In this Editorial review, we would like to discuss the potential of optogenetic approaches in CRC management.

show abstract

“…Colorectal cancer (CRC), featured by aggressive metastasis, recurrence, and poor prognosis, is among the most prevalent and deadly diseases globally. , Current clinical treatments of CRC, including surgery, chemotherapy, , and radiotherapy, are severely limited because of their ineffectiveness, low specificity, and unsatisfactory time/spatial controllability. Therefore, developing precise diagnostic methods and low-damage therapeutic approaches is a crucial step in reducing the mortality rates associated with CRC.…”

mentioning

confidence: 99%

Synergistically Enhanced Chemodynamic Therapy Induced by NIR-II Photothermal Therapy with MRI/CT Imaging Guidance for Colorectal Cancer

Liu,

Hong,

Pan

et al. 2024

ACS Materials Lett.

View full text Add to dashboard Cite

Chemodynamic therapy (CDT) exhibits unsatisfactory therapeutic efficacy for colorectal cancer (CRC) due to the hyposensitive Fenton reaction. Herein, we constructed a novel multifunctional nanoplatform based on bismuth-doped iron selenide nanoparticles (BFS NPs) for promoting the therapeutic performance of CDT on CRC. BFS NPs can realize CDT and second near-infrared photothermal therapy (NIR-II PTT) by means of the Fenton reaction and an excellent photothermal conversion efficiency (η = 31.9%). Moreover, the rising temperature induced by NIR irradiation accelerates the Fenton reaction rate because of there being more activated H 2 O 2 , thereby improving reactive oxygen species (ROS) levels to address the insufficient hydrogen peroxide concentration. The results showed that the combination of CDT with NIR-II PTT significantly inhibits the growth of CRC and minimizes adverse reactions. Meanwhile, bismuth doping endows the BFS NPs with superior CT imaging and T 2 -weighted magnetic resonance imaging (T 2 -MRI) capacities. These unique properties offer an appropriate treatment time window for guiding NIR-II PTT. In summary, this nanoplatform improves the therapeutic effect of CDT and accurately regulates NIR-II PTT by MRI/ CT imaging guidance, which provides a new perspective for effective and precise therapy of CRC.

show abstract

Cabazitaxel suppresses colorectal cancer cell growth via enhancing the p53 antitumor pathway

Cited by 5 publications

References 33 publications

Clinical implications of PD-L1 expression and pathway-related molecular subtypes in advanced Asian colorectal cancer patients

Clinical implications of PD-L1 expression and pathway-related molecular subtypes in advanced Asian colorectal cancer patients

Recent clinical trials and optical control as a potential strategy to develop microtubule-targeting drugs in colorectal cancer management

Synergistically Enhanced Chemodynamic Therapy Induced by NIR-II Photothermal Therapy with MRI/CT Imaging Guidance for Colorectal Cancer

Contact Info

Product

Resources

About